Investor Overview

Corporate Profile

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut and other food allergies. Our characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), combines proprietary product candidates with gradual, controlled up-dosing protocols to obtain meaningful desensitization to food allergens.... more >

Recent Newsmore >
August 18, 2016
Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children
─ Academic Study Recently Published in the Journal of Allergy and Clinical Immunology Provides Support for Aimmune’s Planned Pediatric Trial of AR101 ─ ─ Conference Call on Monday, August 22, 2016, at 4:30 p.m. Eastern Time ─ BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 18, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for l... 
August 10, 2016
Aimmune Therapeutics Announces Second Quarter 2016 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 10, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced financial results for the second quarter of 2016. For the quarter and six months ended June 30, 2016, net loss was $18.1 million and $33.7 million, respectively, compared to a net loss of $7.4 mill... 
August 9, 2016
Aimmune Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 9, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that Stephen G. Dilly, M.B.B.S., Ph.D., Chief Executive Officer of Aimmune, will present a company overview at the 2016 Wedbush PacGrow Healthcare Conference in New York City, on Tuesday, August 16,... 
Upcoming Eventsmore >
There are currently no events scheduled.
Email Alerts
Sign up to receive email alerts when Aimmune Therapeutics posts new information to this site. Please enter your email address and click submit below.